Aprea Therapeutics (APRE) provided an update on its existing patent portfolio. Aprea’s ATR inhibitor program is protected by ...

DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) has announced significant advancements in its intellectual property ...

Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while ...

DOYLESTOWN, Pa. - Aprea Therapeutics, Inc. (NASDAQ: NASDAQ:APRE), a biopharmaceutical company with a market capitalization of $21.2 million focused on developing treatments targeting cancer cell ...

宾夕法尼亚州多伊尔斯镇 - 市值2,120万美元的生物制药公司Aprea Therapeutics, Inc. (NASDAQ: APRE)宣布更新其专利组合。该公司专注于开发针对癌细胞脆弱性的治疗方案。根据 InvestingPro 数据显示，公司股票目前交易价格为3.90美元，年初至今上涨18.54%。公司总裁兼首席执行官Oren ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

Dr. Cigler, who serves as co-principal investigator for the initiative, will work alongside Dr. Vered Stearns and a multidisciplinary team at Weill Cornell Medicine to address the unique needs of ...